PortfoliosLab logoPortfoliosLab logo
BAX vs. PFE
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BAX vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Baxter International Inc. (BAX) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BAX achieves a 2.98% return, which is significantly lower than PFE's 4.10% return. Over the past 10 years, BAX has underperformed PFE with an annualized return of -6.26%, while PFE has yielded a comparatively higher 1.96% annualized return.


BAX

1D
-1.16%
1M
2.56%
YTD
2.98%
6M
3.69%
1Y
-33.88%
3Y*
-22.55%
5Y*
-23.11%
10Y*
-6.26%

PFE

1D
-0.52%
1M
-3.17%
YTD
4.10%
6M
2.82%
1Y
11.94%
3Y*
-7.59%
5Y*
-3.66%
10Y*
1.96%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BAX vs. PFE - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BAX
Baxter International Inc.
2.98%-33.28%-22.40%-21.91%-39.58%8.48%-2.95%28.40%2.89%47.30%
PFE
Pfizer Inc.
4.10%0.65%-2.22%-41.26%-10.41%66.70%3.07%-6.91%24.82%15.90%

Correlation

The correlation between BAX and PFE is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.44

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.34

Correlation (10Y)
Calculated over the trailing 10-year period

0.37

Correlation (All Time)
Calculated using the full available price history since Oct 27, 1981

0.37

Fundamentals

Market Cap

BAX:

$10.12B

PFE:

$143.73B

EPS

BAX:

-$1.74

PFE:

$1.31

PS Ratio

BAX:

0.89

PFE:

2.26

PB Ratio

BAX:

1.68

PFE:

1.60

Total Revenue (TTM)

BAX:

$11.32B

PFE:

$63.32B

Gross Profit (TTM)

BAX:

$3.41B

PFE:

$43.91B

EBITDA (TTM)

BAX:

$399.00M

PFE:

$16.94B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BAX vs. PFE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BAX
BAX Risk / Return Rank: 1515
Overall Rank
BAX Sharpe Ratio Rank: 1111
Sharpe Ratio Rank
BAX Sortino Ratio Rank: 1515
Sortino Ratio Rank
BAX Omega Ratio Rank: 1313
Omega Ratio Rank
BAX Calmar Ratio Rank: 1616
Calmar Ratio Rank
BAX Martin Ratio Rank: 2121
Martin Ratio Rank

PFE
PFE Risk / Return Rank: 5858
Overall Rank
PFE Sharpe Ratio Rank: 6060
Sharpe Ratio Rank
PFE Sortino Ratio Rank: 5454
Sortino Ratio Rank
PFE Omega Ratio Rank: 5252
Omega Ratio Rank
PFE Calmar Ratio Rank: 6464
Calmar Ratio Rank
PFE Martin Ratio Rank: 6262
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BAX vs. PFE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Baxter International Inc. (BAX) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BAXPFEDifference
Sharpe ratioReturn per unit of total volatility

-1.23

Sortino ratioReturn per unit of downside risk

-1.69

Omega ratioGain probability vs. loss probability

0.88

1.11

-0.23

Calmar ratioReturn relative to maximum drawdown

-0.69

1.05

-1.74

Martin ratioReturn relative to average drawdown

-1.00

2.06

-3.06

BAX vs. PFE - Sharpe Ratio Comparison

The current BAX Sharpe Ratio is -0.73, which is lower than the PFE Sharpe Ratio of 0.50. The chart below compares the historical Sharpe Ratios of BAX and PFE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BAX vs. PFE - Drawdown Comparison

The maximum BAX drawdown since its inception was -81.15%, which is greater than PFE's maximum drawdown of -69.24%. Use the drawdown chart below to compare losses from any high point for BAX and PFE.


Loading charts...

Drawdown Indicators


BAXPFEDifference

Max Drawdown

Largest peak-to-trough decline

-81.15%

-69.24%

-11.91%

Max Drawdown (1Y)

Largest decline over 1 year

-49.00%

-11.47%

-37.53%

Max Drawdown (3Y)

Largest decline over 3 years

-65.90%

-37.69%

-28.21%

Max Drawdown (5Y)

Largest decline over 5 years

-80.61%

-58.96%

-21.65%

Max Drawdown (10Y)

Largest decline over 10 years

-81.15%

-58.96%

-22.19%

Current Drawdown

Current decline from peak

-76.53%

-48.02%

-28.51%

Average Drawdown

Average peak-to-trough decline

-21.68%

-22.91%

+1.23%

Ulcer Index

Depth and duration of drawdowns from previous peaks

34.04%

5.80%

+28.24%

Volatility

BAX vs. PFE - Volatility Comparison

Baxter International Inc. (BAX) has a higher volatility of 10.05% compared to Pfizer Inc. (PFE) at 5.40%. This indicates that BAX's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BAXPFEDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.05%

5.40%

+4.65%

Volatility (6M)

Calculated over the trailing 6-month period

32.53%

14.21%

+18.32%

Volatility (1Y)

Calculated over the trailing 1-year period

46.76%

23.93%

+22.83%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

33.89%

25.50%

+8.39%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

29.36%

23.91%

+5.45%

Dividends

BAX vs. PFE - Dividend Comparison

BAX's dividend yield for the trailing twelve months is around 1.02%, less than PFE's 6.86% yield.


PositionTTM20252024202320222021202020192018201720162015
BAX
Baxter International Inc.
1.02%2.72%3.57%3.00%2.26%1.26%1.19%1.02%1.11%0.94%1.14%87.05%
PFE
Pfizer Inc.
6.86%6.91%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.53%3.69%3.47%

Financials

BAX vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Baxter International Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


5.00B10.00B15.00B20.00B25.00B20222023202420252026
2.70B
14.45B
(BAX) Total Revenue
(PFE) Total Revenue
Values in USD except per share items

BAX vs. PFE - Profitability Comparison

The chart below illustrates the profitability comparison between Baxter International Inc. and Pfizer Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%20222023202420252026
33.0%
67.3%
Portfolio components
BAX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Baxter International Inc. reported a gross profit of 891.00M and revenue of 2.70B. Therefore, the gross margin over that period was 33.0%.

PFE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.

BAX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Baxter International Inc. reported an operating income of -42.00M and revenue of 2.70B, resulting in an operating margin of -1.6%.

PFE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.

BAX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Baxter International Inc. reported a net income of 190.00M and revenue of 2.70B, resulting in a net margin of 7.0%.

PFE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.


Frequently Asked Questions


BAX and PFE have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BAX has higher volatility (10.05%) compared to PFE (5.40%). In terms of maximum drawdown, BAX dropped -81.15% vs PFE's -69.24%.

PFE currently has the higher Sharpe Ratio (0.50 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BAX and PFE

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer